Combination therapies using cyclosporine and aromatic cationic peptides
AssigneeStealth BioTherapeutics Inc.
InventorD. Travis Wilson
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for preventing or treating an ischemia-reperfusion injury, such as occurs during acute myocardial infarction and organ transplant in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, and one or more additional active agents such as cyclosporine.
Claims20
A method for treating ischemia and/or reperfusion injury in a subject in need thereof, the method comprising administering simultaneously, separately or sequentially an effective amount of (i) an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, wherein the aromatic-cationic peptide is selected from the group consisting of:
- Tyr-D-Arg-Phe-Lys-NH2;
- 2′,6′-Dmt-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2;
- 2′,6′-Dmp-D-Arg-Phe-Lys-NH2;
- and D-Arg-2′,6′-Dmt-Lys-Phe-NH2 and (ii) an additional active agent selected from the group consisting of cyclosporine, or a functional derivative or analogue thereof.
A pharmaceutical composition comprising (i) an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, wherein the aromatic-cationic peptide is selected from the group consisting of:
- Tyr-D-Arg-Phe-Lys-NH2;
- 2′,6′-Dmt-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2;
- 2′,6′-Dmp-D-Arg-Phe-Lys-NH2;
- and D-Arg-2′,6′-Dmt-Lys-Phe-NH2, and (ii) an additional active agent selected from the group consisting of cyclosporine, or a functional derivative or analogue thereof.
The pharmaceutical composition of claim 6, wherein the pharmaceutically acceptable salt comprises acetate salt or trifluororacetate salt.
A composition comprising:
- an (i) an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, wherein the aromatic-cationic peptide is selected from the group consisting of:
- Tyr-D-Arg-Phe-Lys-NH2;
- 2′,6′-Dmt-D-Arg-Phe-Lys-NH2;
- Phe-D-Arg-Phe-Lys-NH2;
- 2′,6′-Dmp-D-Arg-Phe-Lys-NH2;
- and D-Arg-2′,6′-Dmt-Lys-Phe-NH2, and (ii) an additional active agent selected from the group consisting of cyclosporine, or a functional derivative or analogue thereof;
- wherein the aromatic-cationic peptide is linked to the active agent by a linker.
The composition of claim 10, wherein the pharmaceutically acceptable salt comprises acetate salt or trifluororacetate salt.
Dependencies are inferred from the claim text.